These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1379 related items for PubMed ID: 9628768

  • 1. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 2. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [Abstract] [Full Text] [Related]

  • 3. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK, Banerji T, Jenner P, Marsden CD.
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [Abstract] [Full Text] [Related]

  • 4. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ.
    Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M, Usiello A, Carta M, Håkansson K, Fisone G, Cenci MA.
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [Abstract] [Full Text] [Related]

  • 6. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL, Geng XC, Zhu XZ.
    Brain Res Bull; 2011 Nov 25; 86(5-6):367-72. PubMed ID: 21963945
    [Abstract] [Full Text] [Related]

  • 7. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V, Sosti V, Rubio A, Barbanoj M, Rodríguez-Alvarez J, Kulisevsky J.
    Eur J Pharmacol; 2007 Dec 08; 576(1-3):83-90. PubMed ID: 17888901
    [Abstract] [Full Text] [Related]

  • 8. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H, Ma L, Wang F, Chen J, Zhen X.
    Neuropharmacology; 2007 Jul 08; 53(1):125-33. PubMed ID: 17553535
    [Abstract] [Full Text] [Related]

  • 9. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 08; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 10. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan 08; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 11. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.
    Brain Res Bull; 2004 Aug 30; 64(2):155-64. PubMed ID: 15342103
    [Abstract] [Full Text] [Related]

  • 12. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
    Lane EL, Cheetham SC, Jenner P.
    Eur J Neurosci; 2005 Jan 30; 21(1):179-86. PubMed ID: 15654855
    [Abstract] [Full Text] [Related]

  • 13. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J, Zhang H, Yu LP, Sun PH, Jin GZ, Zhen X.
    Neurobiol Aging; 2010 Jun 30; 31(6):926-36. PubMed ID: 18707801
    [Abstract] [Full Text] [Related]

  • 14. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb 30; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M.
    Eur J Pharmacol; 2007 Jul 02; 566(1-3):94-102. PubMed ID: 17445798
    [Abstract] [Full Text] [Related]

  • 16. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P.
    J Neurochem; 2010 Jul 02; 114(2):499-511. PubMed ID: 20456008
    [Abstract] [Full Text] [Related]

  • 17. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F, Millan MJ, Brocco M, Morari M.
    Neuropharmacology; 2010 Feb 02; 58(2):528-36. PubMed ID: 19733554
    [Abstract] [Full Text] [Related]

  • 18. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM.
    J Pharmacol Exp Ther; 2010 Jun 02; 333(3):865-73. PubMed ID: 20231306
    [Abstract] [Full Text] [Related]

  • 19. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G, Mora F, Crossman AR, Brotchie JM.
    Mov Disord; 2003 Feb 02; 18(2):138-49. PubMed ID: 12539206
    [Abstract] [Full Text] [Related]

  • 20. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL, Gupta V, Alam S, Park JY, Bishop C.
    Pharmacol Biochem Behav; 2007 Feb 02; 87(3):306-14. PubMed ID: 17553556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.